Cvrx Inc (CVRX) Stock Price, Quote & News

Company Profile

CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular sy...

Industry: Medical Devices

Sector: Healthcare

Phone: 763 416 2840

Fax: 763 416 2841

Website: www.cvrx.com

Address:

9201 West Broadway Avenue, Suite 650, Minneapolis, United States

1111tu May. 13 at 3:09 AM

$CVRX Today’s sell-off is gift. Mgmt did what is said it would do. They met guidance provided last month. Mgmt intimated they will provide upward guidance later in the year.

1 · Reply

Twister8 May. 12 at 11:00 PM

$CVRX pre auth approvals through Medicare advantage are at 50% thus far this year, last year they were 44%. Will Hykes tout that as great execution?

0 · Reply

Twister8 May. 12 at 10:55 PM

$CVRX sales strategy is to get as many new centers onboard with the hopes of some of them doing more than 3/year?

1 · Reply

davidbo May. 12 at 10:19 PM

$CVRX obviously you do not know how to manage this company,time to sell it to somebody who knows what they're doing. you have a awful history and should be ashamed of all yourselves

1 · Reply

MedDevice May. 12 at 8:30 PM

$CVRX 2026 is the year of execution. Kevin Hykes - JPM HC Conference, January 2026

0 · Reply

Twister8 May. 12 at 5:56 PM

$CVRX it is proving out that this expensive mgmt team got paid to rearrange the table and has tried to sell it as something meaningful for investors.

0 · Reply

Twister8 May. 12 at 2:50 PM

$CVRX one down 2,499 to go with estimated completion in year 2032...lol

0 · Reply

Twister8 May. 12 at 2:48 PM

$CVRX how is the new sales team doing?

0 · Reply

EarningsInsider May. 11 at 11:08 PM

https://www.marketbeat.com/earnings/reports/2026-5-11-cvrx-inc-stock/ $CVRX CVRx Earnings Transcript

0 · Reply

MarketBeat May. 11 at 11:06 PM

https://marketbeat.com/a/8648983/ $CVRX CVRx Q1 Earnings Call Highlights

0 · Reply

CVRx, Inc. Earnings Call Transcript: Q1 2026

May 11, 2026, 4:05 PM EDT - 1 day ago

CVRx Reports First Quarter 2026 Financial and Operating Results

2026-05-04T21:15:14.000Z - 8 days ago

CVRx enrolls first patient in BENEFIT-HF trial

May 4, 2026, 4:30 PM EDT - 8 days ago

CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

Apr 27, 2026, 4:30 PM EDT - 15 days ago

CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026

Apr 20, 2026, 4:30 PM EDT - 22 days ago

CVRx Announces Nomination of Michael Dale for Election to the Board of Directors

Apr 9, 2026, 9:00 AM EDT - 4 weeks ago

CVRx, Inc. Investigated by the Portnoy Law Firm

Mar 2, 2026, 8:30 AM EST - 2 months ago

CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting

2026-02-13T12:10:44.000Z - 3 months ago

CVRx price target lowered to $6 from $7 at JPMorgan

2026-02-13T11:55:30.000Z - 3 months ago

CVRx price target lowered to $10 from $11 at Canaccord

Feb 12, 2026, 4:30 PM EST - 3 months ago

CVRx, Inc. Earnings Call Transcript: Q4 2025

Jan 29, 2026, 4:10 PM EST - 3 months ago

CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026

2026-01-22T21:20:25.000Z - 3 months ago

CVRx initiates BENEFIT-HF clinical trial

Jan 22, 2026, 4:05 PM EST - 3 months ago

CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

Jan 14, 2026, 6:45 PM EST - 4 months ago

CVRx, Inc. Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 8:00 AM EST - 4 months ago

CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance

2026-01-06T13:52:44.000Z - 4 months ago

CVRx announces implementation of new category I CPT codes for Barostim therapy

Jan 6, 2026, 8:30 AM EST - 4 months ago

CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy

Dec 22, 2025, 8:30 AM EST - 5 months ago

CVRx to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 3, 2025, 2:00 PM EST - 5 months ago

CVRx, Inc. Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 19, 2025, 8:30 AM EST - 6 months ago

CVRx to Participate at the Piper Sandler 37th Annual Healthcare Conference

Nov 18, 2025, 3:00 AM EST - 6 months ago

CVRx, Inc. Transcript: Jefferies London Healthcare Conference 2025

2025-11-06T13:55:34.000Z - 6 months ago

CVRx files $150M mixed securities shelf

2025-11-06T13:51:58.000Z - 6 months ago

CVRx price target raised to $13 from $11 at Cantor Fitzgerald

2025-11-06T13:38:03.000Z - 6 months ago

CVRx price target raised to $11 from $9 at Canaccord

2025-11-05T21:37:21.000Z - 6 months ago

CVRx sees Q4 revenue $15M-$16M, consensus $15.85M

Nov 5, 2025, 4:30 PM EST - 6 months ago

CVRx, Inc. Earnings Call Transcript: Q3 2025

Oct 22, 2025, 4:30 PM EDT - 7 months ago

CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025

Aug 12, 2025, 3:00 PM EDT - 9 months ago

CVRx, Inc. Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 4, 2025, 4:30 PM EDT - 10 months ago

CVRx, Inc. Earnings Call Transcript: Q2 2025

Aug 4, 2025, 4:05 PM EDT - 10 months ago

CVRx Reports Second Quarter 2025 Financial and Operating Results

Jul 29, 2025, 8:30 AM EDT - 10 months ago

CVRx to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 16, 2025, 7:30 AM EDT - 10 months ago

CVRx Announces Positive News on Outpatient Payment for Barostim

Jun 4, 2025, 11:00 AM EDT - 1 year ago

CVRx, Inc. Transcript: 45th Annual William Blair Growth Stock Conference

May 28, 2025, 4:30 PM EDT - 1 year ago

CVRx to Present at the William Blair 45th Annual Growth Stock Conference

May 8, 2025, 4:30 PM EDT - 1 year ago

CVRx, Inc. Earnings Call Transcript: Q1 2025

Apr 24, 2025, 4:30 PM EDT - 1 year ago

CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025

Apr 7, 2025, 4:05 PM EDT - 1 year ago

CVRx Reports Preliminary First Quarter 2025 Financial Results

Feb 12, 2025, 2:45 PM EST - 1 year ago

CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim

Feb 4, 2025, 4:30 PM EST - 1 year ago

CVRx, Inc. Earnings Call Transcript: Q4 2024

Feb 4, 2025, 4:05 PM EST - 1 year ago

CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Jan 21, 2025, 4:30 PM EST - 1 year ago

CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025

Jan 15, 2025, 5:15 PM EST - 1 year ago

CVRx, Inc. Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Dec 23, 2024, 4:30 PM EST - 1 year ago

CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 4, 2024, 3:30 PM EST - 1 year ago

CVRx, Inc. Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 20, 2024, 4:30 PM EST - 1 year ago

CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference

Oct 29, 2024, 4:30 PM EDT - 1 year ago

CVRx, Inc. Earnings Call Transcript: Q3 2024

Oct 18, 2024, 2:08 PM EDT - 1 year ago

CVRx announces new CPT® Category I codes for Barostim

Oct 15, 2024, 4:30 PM EDT - 1 year ago

CVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024

Sep 3, 2024, 8:30 AM EDT - 1 year ago

CVRx Announces Appointment of Two New Board Members

1111tu May. 13 at 3:09 AM

$CVRX Today’s sell-off is gift. Mgmt did what is said it would do. They met guidance provided last month. Mgmt intimated they will provide upward guidance later in the year.

1 · Reply

Twister8 May. 12 at 11:00 PM

$CVRX pre auth approvals through Medicare advantage are at 50% thus far this year, last year they were 44%. Will Hykes tout that as great execution?

0 · Reply

Twister8 May. 12 at 10:55 PM

$CVRX sales strategy is to get as many new centers onboard with the hopes of some of them doing more than 3/year?

1 · Reply

davidbo May. 12 at 10:19 PM

$CVRX obviously you do not know how to manage this company,time to sell it to somebody who knows what they're doing. you have a awful history and should be ashamed of all yourselves

1 · Reply

MedDevice May. 12 at 8:30 PM

$CVRX 2026 is the year of execution. Kevin Hykes - JPM HC Conference, January 2026

0 · Reply

Twister8 May. 12 at 5:56 PM

$CVRX it is proving out that this expensive mgmt team got paid to rearrange the table and has tried to sell it as something meaningful for investors.

0 · Reply

Twister8 May. 12 at 2:50 PM

$CVRX one down 2,499 to go with estimated completion in year 2032...lol

0 · Reply

Twister8 May. 12 at 2:48 PM

$CVRX how is the new sales team doing?

0 · Reply

EarningsInsider May. 11 at 11:08 PM

https://www.marketbeat.com/earnings/reports/2026-5-11-cvrx-inc-stock/ $CVRX CVRx Earnings Transcript

0 · Reply

MarketBeat May. 11 at 11:06 PM

https://marketbeat.com/a/8648983/ $CVRX CVRx Q1 Earnings Call Highlights

0 · Reply

Convinvestor May. 11 at 8:26 PM

$CVRX Talk about an off the radar stock... almost no reaction to Q earnings. which seem good, lets hear the call. adding position.

3 · Reply

StocktwitsEarnings May. 11 at 8:16 PM

$CVRX Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.50 up 5.66% YoY • Reported revenue of $14.77M up 19.61% YoY • For full year 2026, CVRx maintained revenue guidance between $63M and $67M, and operating expenses between $103M and $107M, while updating gross margin to 85% to 87%.

0 · Reply

InfernoGaze May. 4 at 5:19 AM

$CVRX Preliminary Q1 2026 Results: On April 13, 2026, CVRx reported preliminary revenue of $14.7 million to $14.8 million, representing approximately 20% growth year-over-year.

0 · Reply

1111tu Apr. 28 at 1:51 AM

$CVRX https://ir.cvrx.com/news-releases/news-release-details/cvrx-report-first-quarter-2026-financial-and-operating-results/

0 · Reply

1111tu Apr. 24 at 4:45 PM

$CVRX Annual Shareholder Mtg at 10:00 CDT May 1. It’s an online event only.

1 · Reply

1111tu Apr. 23 at 1:07 PM

$CVRX. Addresses patient population targeted by Benefit HF Trial. New HFSA Scientific Statement Provides Practical Guidance for Managing Heart Failure with Mildly Reduced Ejection Fraction | HFSA https://hfsa.org/new-hfsa-scientific-statement-provides-practical-guidance-managing-heart-failure-mildly-reduced

2 · Reply

1111tu Apr. 22 at 8:02 PM

$CVRX Any ideas why management pre-announced Q1? I don’t recall them doing that previously. They understandably have pre-announced Q4 the past few years while they compiled full year results , but not Q1. Did they make a public presentation requiring the pre-announcement of financials? No presentation is posted on their IR Event webpage calendar.

1 · Reply

1111tu Apr. 20 at 10:50 PM

$CVRX @MedDevice Mgmt has publicly disclosed that their highest volume cohort of 50 sites installs avg 19/yr. So approximately 240 implants in Q4 25. This means the remaining 202 sites had 238 implants. Therefore ~50% of sales were earned in the top 19 accounts and 50% outside the top 19. It also means that most of the sales territories outside of the those that cover the 19 accounts don’t sell enough product to cover their own salaries. Hykes said that the high volume accounts see less than 7% of their qualifying HF patients receive a Barostim. That said, I’m sure the reps know it, management knows it, and there’s nothing like pressure to focus attention to accounts where growth can happen. This is a binary proposition.

1 · Reply

focafoca99 Apr. 20 at 9:37 PM

$CVRX nominated Michael Dale for election to its board at the June 1 annual meeting.

0 · Reply

MedDevice Apr. 20 at 2:01 AM

$CVRX Not a margin expansion story, this is a growth story. Implant growth simply isn’t happening in the US on a same store sales basis. The reported increase in insurance prior authorization approval rates will be confirmed in the next quarter, 6 months into the new year, for outpatient claims.

1 · Reply

OfficialStocktwitsUser Apr. 17 at 1:21 PM

$CVRX RSI: 28.71, MACD: -0.1255 Vol: 0.73, MA20: 8.43, MA50: 7.63 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

MITornado Apr. 14 at 1:40 PM

$CVRX lowball price here… 60 million revenue bare minimum this year if q1 looks this strong . 200 million valuation for a med device start up is absolutely awful.

1 · Reply

Market Cap	182.90M
Revenue (ttm)	56.65M
Net Income (ttm)	-53.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-94.10%
Debt to Equity Ratio	1.26

Volume	864,200
Avg Vol	253,438
Day's Range	N/A - N/A
Shares Out	26.43M
Stochastic %K	2%
Beta	0.90
Analysts	Strong Sell
Price Target	$11.17